Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 3 11Phase NA 10Phase 2/3 2Phase 1/2 2Phase 4 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1

Conditions

Esophageal Squamous Cell Carcinoma 2

Interventions

Oxaliplatin 49Fluorouracil 46Capecitabine 41Cisplatin 36Gemcitabine 29Leucovorin 27Bevacizumab 21Drug Therapy 20Paclitaxel 15Folfox protocol 15Radiotherapy 14Irinotecan 14apatinib 11Neoadjuvant Therapy 11Docetaxel 11sintilimab 9S 1 (combination) 9Trastuzumab 8Sorafenib 8Nivolumab 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 7lenvatinib 6atezolizumab 6XELOX 6Cetuximab 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6tislelizumab 5pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Esophagectomy × Gastrointestinal × Clear all
NCT05213312 2022-06-15

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Shanghai Zhongshan Hospital

Phase 2/3 Unknown
90 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03623737 2022-06-07

Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC

National Taiwan University Hospital

Phase 2/3 Unknown
248 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡